Antithrombotic properties of hemofilter coated with polymer having a hydrophilic blood-contacting layer.


Journal

The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 30 11 2018
medline: 16 4 2019
entrez: 30 11 2018
Statut: ppublish

Résumé

Extracorporeal circulation devices are coated with a biocompatible polymer coating agent (BPCA) that has a hydrophilic blood-contacting layer, but hemofilters are not. We aimed to investigate the antithrombotic properties of a BPCA-coated hemofilter. Four experiments using BPCA-coated circuits and non-coated hemofilters and four experiments using BPCA-coated circuits and BPCA-coated hemofilters were performed with whole human blood and compared by measuring the circuit pressure every 5 min, antithrombin activity every 40 min, and thrombin-antithrombin complex every 40 min, for a total of 240 min of recirculation. The mean time required for the pressure at the inlet of the hemofilter to increase sharply was longer in BPCA-coated than in non-coated hemofilters (66 ± 11 min vs 25 ± 9 min, p < 0.01). The mean antithrombin activity value at 200 and 240 min of recirculation was significantly higher in the experiments with BPCA-coated versus non-coated hemofilters (43.3 ± 2.87 vs 33.3 ± 5.74, p = 0.04; 42.8 ± 3.59 vs 31.0 ± 5.35, p = 0.01, respectively); the antithrombin activity values at the other time points were not significantly different. Furthermore, all thrombin-antithrombin complex values in experiments with the BPCA-coated hemofilters achieved overrange at 80 min of recirculation, whereas those with the non-coated hemofilter achieved overrange at 40 min. This study suggests that BPCA-coated hemofilters can inhibit antithrombin consumption, contributing to antithrombotic effects in extracorporeal circulation circuits.

Identifiants

pubmed: 30486706
doi: 10.1177/0391398818815480
pmc: PMC6343425
doi:

Substances chimiques

Acrylates 0
Antithrombins 0
Coated Materials, Biocompatible 0
Polymers 0
Sulfones 0
antithrombin III-protease complex 0
polyether sulfone 25667-42-9
Antithrombin III 9000-94-6
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-94

Références

Perfusion. 2009 Jul;24(4):231-7
pubmed: 19858237
J Am Soc Nephrol. 2005 Aug;16(8):2421-30
pubmed: 15975998
Perfusion. 2015 Oct;30(7):572-9
pubmed: 25837980
J Extra Corpor Technol. 2006 Mar;38(1):27-32
pubmed: 16637520
Artif Organs. 2006 Feb;30(2):106-10
pubmed: 16433843
Thorac Cardiovasc Surg. 1985 Apr;33(2):81-5
pubmed: 2409629
J Extra Corpor Technol. 2012 Mar;44(1):21-5
pubmed: 22730860
Anesth Analg. 2010 Oct;111(4):862-9
pubmed: 19820236
J Am Soc Nephrol. 2013 Mar;24(4):529-36
pubmed: 23349311
Int J Artif Organs. 2017 Nov 24;40(12):665-669
pubmed: 28777393
Clin Chem. 1988 Oct;34(10):2058-62
pubmed: 3168216
Blood Coagul Fibrinolysis. 2002 Dec;13(8):657-70
pubmed: 12441904
Crit Care. 2006;10(2):R45
pubmed: 16542495
N Engl J Med. 2002 Dec 19;347(25):2010-9
pubmed: 12490682
Perfusion. 2015 May;30(4):318-22
pubmed: 25118198
Perfusion. 2014 Mar;29(2):117-23
pubmed: 23985424
Int J Artif Organs. 2002 Sep;25(9):875-81
pubmed: 12403404
Int J Artif Organs. 2016 Oct 10;39(8):415-420
pubmed: 27646632
Nephron Clin Pract. 2003;94(4):c83-4
pubmed: 12972716
Thromb Res. 2013;132(6):671-5
pubmed: 24144445
J Artif Organs. 2008;11(3):111-6
pubmed: 18836870
J Artif Organs. 2003;6(4):260-6
pubmed: 14691668
Nephrol Dial Transplant. 1998;13 Suppl 6:148-51
pubmed: 9719222
Blood Purif. 2011;32(3):151-5
pubmed: 21659742
Open Access Emerg Med. 2017 Dec 28;10:25-29
pubmed: 29343993
Nephrol Dial Transplant. 2007 Oct;22(10):2978-84
pubmed: 17597089
Intensive Care Med. 2012 Nov;38(11):1818-25
pubmed: 22773036
J Extra Corpor Technol. 2014 Sep;46(3):262-6
pubmed: 26357794
Mater Sci Eng C Mater Biol Appl. 2013 Jul 1;33(5):3041-6
pubmed: 23623130
Crit Care. 2014 Jan 13;18(1):R13
pubmed: 24410881
Biomaterials. 2002 Sep;23(18):3897-903
pubmed: 12164195
Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):331-2
pubmed: 18187458
J Biomater Sci Polym Ed. 2006;17(4):449-60
pubmed: 16768295
Blood Coagul Fibrinolysis. 2013 Jun;24(4):454-7
pubmed: 23343694
Am J Hematol. 1991 Oct;38(2):86-9
pubmed: 1951313
ASAIO J. 2005 Jul-Aug;51(4):348-51
pubmed: 16156297
Int J Artif Organs. 2005 Aug;28(8):834-40
pubmed: 16211534

Auteurs

Masashi Tagaya (M)

1 Department of Medical Engineering, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Kazunobu Hara (K)

1 Department of Medical Engineering, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Shunsuke Takahashi (S)

2 Department of Nephrology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Saki Nagoshi (S)

3 Department of Clinical Laboratory, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Hiroki Handa (H)

1 Department of Medical Engineering, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Shinya Okano (S)

1 Department of Medical Engineering, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Takuo Murataka (T)

1 Department of Medical Engineering, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH